Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ORMP

Oramed Pharmaceuticals Inc.

Healthcare | Biotechnology

No licensed closing price on file for ORMP. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$1.50

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 07:44 UTC.

What Oramed Pharmaceuticals Inc. does

The company is a pharmaceutical firm developing an oral delivery technology platform for therapeutic proteins, with a particular focus on oral insulin that can withstand the gastrointestinal tract without chemically modifying the proteins. Beyond core pharmaceutical research and development, the company makes strategic investments in healthcare and life sciences companies to complement its technology focus and enhance shareholder value.

Summarized from Oramed Pharmaceuticals Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (FY2025)$1.50
Return on equity32.07%

Revenue, margins & earnings

FY2021: net loss $23M on revenue $3M$3MFY2021FY2022: net loss $37M on revenue $3M$3MFY2022FY2023 Revenue: $1M — margin split not shown (non-operating gains)FY2023: net income $5M exceeded revenue $1M by $4M — non-operating gains (e.g. asset sales), not operating profit$1MFY2023FY2025 Revenue: $2M — margin split not shown (non-operating gains)FY2025: net income $64M exceeded revenue $2M by $62M — non-operating gains (e.g. asset sales), not operating profit$2MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net income above revenue (non-operating gains)
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
Gold cap: net income exceeded revenue that year from non-operating gains (e.g. asset sales), not operating profit.
Net income for FY2022 is the filer’s available-to-common figure (net of preferred dividends) — the filer tags no parent net income for those years.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-02
  • 2026-10-02COO & CBOSale-30,000$135.3K
  • 2026-10-02Chief Financial OfficerSale-20,000$90.2K
  • 2026-09-25Chief Scientific OfficerStock option (right to buy)Returned to company-47,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Oramed Pharmaceuticals Inc. do?

The company is a pharmaceutical firm developing an oral delivery technology platform for therapeutic proteins, with a particular focus on oral insulin that can withstand the gastrointestinal tract without chemically modifying the proteins.

When did ORMP last file with the SEC?

Oramed Pharmaceuticals Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-30. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 07:44 UTC. This page is also available as JSON at /api/data?ticker=ORMP and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ORMP and 5,000+ tickers.

Create a free account — keep ORMP
For your agent
GET /api/data?ticker=ORMP

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt